New chelation therapies and emerging chelating drugs for the treatment of iron overload.

about

What is new in iron overload?Iron overload in myelodysplastic syndromes (MDS) - diagnosis, management, and response criteria: a proposal of the Austrian MDS platform Effects of combined deferiprone and deferoxamine chelation therapy on iron load indices in beta-thalassemia.

P2860

Q36953320-FB9F3D6E-6C1A-42EB-914D-914956733E5A Q39529378-E65B196E-BA81-4346-A08D-0AE5A2CAD61C Q46753932-52FCB863-07E0-4C36-8B43-80C69D3BAE88

P2860

New chelation therapies and emerging chelating drugs for the treatment of iron overload.

Item

http://www.wikidata.org/entity/Q46965074

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年学术文章

@wuu

2006年学术文章

@zh

2006年学术文章

@zh-cn

2006年学术文章

@zh-hans

2006年学术文章

@zh-my

2006年学术文章

@zh-sg

2006年學術文章

@yue

2006年學術文章

@zh-hant

name

New chelation therapies and emerging chelating drugs for the treatment of iron overload.

@en

New chelation therapies and emerging chelating drugs for the treatment of iron overload.

@nl

type

Item

label

New chelation therapies and emerging chelating drugs for the treatment of iron overload.

@en

New chelation therapies and emerging chelating drugs for the treatment of iron overload.

@nl

prefLabel

New chelation therapies and emerging chelating drugs for the treatment of iron overload.

@en

New chelation therapies and emerging chelating drugs for the treatment of iron overload.

@nl

P1476

New chelation therapies and emerging chelating drugs for the treatment of iron overload.

@en

P2093

George J Kontoghiorghes

http://www.w3.org/2001/XMLSchema#string

P2860

Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial.

Benefits and risks of deferiprone in iron overload in Thalassaemia and other conditions: comparison of epidemiological and therapeutic aspects with deferoxamine.

Iron-chelating therapy with the new oral agent ICL670 (Exjade).

Advances in iron overload therapies. prospects for effective use of deferiprone (L1), deferoxamine, the new experimental chelators ICL670, GT56-252, L1NA11 and their combinations.

Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia.

Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2* cardiovascular magnetic resonance.

First human studies with a high-molecular-weight iron chelator.

Ultrastructural pathology of the heart in patients with beta-thalassaemia major.

P304

1-5

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14728214.11.1.1

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2006-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16503822

http://www.w3.org/2001/XMLSchema#string

P921

chelation therapy

New chelation therapies and emerging chelating drugs for the treatment of iron overload.

about

P2860

P2860

New chelation therapies and emerging chelating drugs for the treatment of iron overload.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P921